Trilavir E Tablet is a combination medication designed for the treatment of HIV-1 infection, providing a comprehensive approach to antiretroviral therapy. Each tablet contains three active ingredients: Emtricitabine (200 mg), Tenofovir disoproxil fumarate (300 mg), and Efavirenz (600 mg). Emtricitabine and Tenofovir disoproxil fumarate are both nucleoside reverse transcriptase inhibitors (NRTIs) that work by blocking the reverse transcriptase enzyme, which is crucial for the replication of the HIV virus. Efavirenz, a non-nucleoside reverse transcriptase inhibitor (NNRTI), further enhances the effectiveness of the treatment by inhibiting the same enzyme through a different mechanism. This combination not only helps in reducing the viral load in the body but also aids in improving the immune system’s function, making it a vital option for individuals living with HIV. Trilavir E Tablet is typically prescribed as part of a comprehensive treatment plan that includes regular monitoring and adherence to dosage guidelines to ensure optimal therapeutic outcomes.